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Abstract. Complex variant 9;22 translocations occur in a
significant minority of chronic myelogenous leukaemia (CML)
patients. Different mechanisms of their formation have been
described. We report dual colour dual fusion fluorescence
in situ hybridisation data in 12 Chinese CML patients with
complex translocations. Three previously reported breakpoint
hotspots in a third partner chromosome (14q32, 17q25, 1q21)
were observed. In 10/12 (83.3%) patients, the abnormality
occurred as a single step 3-break event. Only a single
abnormal clone harbouring the complex translocation was
seen in this group. The remaining 2 cases in the chronic phase
showed a 4-break mechanism (2/12, 16.7%). Deletion of 5' ABL
at der(9) was not observed in any of the 12 patients, however,
the loss of 3' BCR was observed in 1 patient (1/12, 8.3%).
Together with previous findings, these data suggest that these
variant translocations occur more often as a 3-break single-
step process with no reciprocal ABL-BCR fusion. On the
other hand, a 4-break event is also regularly seen during the
initial stages of leukaemogenesis, which likely predisposes to
der(9) deletion. The observed difference in rates of der(9)
deletion reported in a series of CML patients with variant
translocations may be related to a difference in rates of a
4-break event.
Introduction
Complex variant translocation of (9;22) has an incidence of
~10% in patients with chronic myelogenous leukaemia (CML)
(1,2). The most common is a 3-way balanced t(9;22;v).
Previous studies using a chromosome 22 painting probe
indicated either a one-step (3) or two-step process (4) in the
genesis of these variants. Recent studies using the fluorescence
in situ hybridisation (FISH) method showed the occurrence
of either mechanism in different and occasionally the same
cases (5,6).
Chronic myelogenous leukaemia with der(9) deletion has
been shown to carry a poor prognosis (7-10). Complex variant
translocations in CML have been reported in many studies to
be associated with a significantly higher incidence of der(9)
deletion than CML with classical Ph translocation (weighted
average 40.4 vs 12.7%) (reviewed in ref. 6). These trans-
locations impart a poor survival to this group of patients
when compared to CML patients with classical t(9;22) or
variant translocations without der(9) deletion (5).
In this study, we employed D-FISH to investigate the
mechanism of formation of the most common 3-way t(9;22;v)
in 12 Chinese patients with CML. The incidence of der(9)
deletion was also determined in this cohort of patients.
Materials and methods
Clinical samples. A search for complex variant translocation
in CML patients was performed in our cytogenetics database.
Twelve cases were identified which had available materials
for D-FISH analysis - 10 in the chronic phase and 2 in the
accelerated phase. All showed a balanced 3-way t(9;22;v).
Conventional cytogenetic analysis. Cytogenetic analysis was
performed on Giemsa banded (G banded) metaphases obtained
through short-term synchronised and unsynchronised cultures
of bone marrow cells based on standardised protocols.
Karyotypes were reported in accordance with ISCN 1995.
D-FISH. Detection of BCR-ABL and ABL-BCR gene fusions
was performed using BCR/ABL dual colour dual fusion
translocation probes (Abbott Molecular/Vysis, Des Plaines,
IL), according to the manufacturer's instructions. In total, 300
interphase nuclei on cytospin smears were analysed for the
presence of fusion signals. In selected cases, metaphase FISH
was performed on G banded metaphases relocated using
microscope coordinates, as described previously (11). A
2G2O1F pattern indicated a one-step 3-break event whereas a
1G1O2F pattern indicated a two-step 4-break event.
Results
Table I shows the disease status during the investigation
and full karyotype of the 12 cases with balanced 3-way
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translocations. Ten patients were in the chronic phase and 2
in the accelerated phase. No patient was in the blast phase.
None of them had received tyrosine kinase inhibitor therapy
prior to investigation. Residual normal metaphases were
detected in only 1 case by conventional cytogenetics.
Recurrent breakpoints in a third partner chromosome were
observed at 5q11.2 (n=2) and 10p14 (n=2). Clonal evolution
was evident in 2 cases. Case 9 showed a subclone with
additional trisomy 8 at disease acceleration. Case 12
harboured a stem line with classical t(9;22), which was not
seen in any other case in this series.
In 10 cases, D-FISH revealed (8 chronic and 2 in the
accelerated phase) a 2G2O1F pattern indicating a one-step
3-break event. A reciprocal ABL-BCR fusion signal was
absent. Normal cells with a 2G2O pattern were observed in 3
of these 10 cases in significant proportions (8-22%) of
interphase nuclei examined. In the remaining 2 cases of the
chronic phase CML, a 1G1O2F pattern was seen indicating a
two-step 4-break mechanism. This included the only case
(Case 12) showing a stemline with classical t(9;22) and
another case (Case 11) with a single abnormal clone of variant
translocation. Metaphase FISH analysis of these 2 cases
showed the presence of a fusion signal on der(9), indicating an
intact ABL-BCR fusion gene and a further break distal to the
ABL breakpoint in the 3-way translocation (Fig. 1a, b and c).
None of the 12 cases showed a loss of the 5' ABL signal on
der(9), however, the loss of the 3' BCR signal on der(9) was
observed in a subclone in 1 case (Case 11). The rate of der(9)
deletion was thus 1/12 (8.3%).
Discussion
In CML, the most common form of complex variant trans-
locations is 3-way balanced t(9;22;v). Indirect evidence
suggests a one-step process in the formation of these variant
translocations in most incidences: i) They are usually observed
at initial diagnosis of the chronic phase, although are not
normally detected as new cytogenetic abnormalities during
disease evolution. ii) By themselves they do not signify
disease acceleration. iii) These variants are most often found
in the absence of a clone bearing classical t(9;22).
The availability of D-FISH provides a useful tool in
investigating the mechanism of the formation of these variant
translocations in CML. Using this technique, a 3-break process
(2G2O1F) and a 4-break two-step process (1G1O2F) have
both been observed. The expected predominance of a 3-break
process was confirmed, which accounted for ~50% of the cases
in recent large series (5,6). However, a significant minority
of cases with a 4-break two-step process was regularly seen
(1,5,6). The incidence ranged from 6 to 21.4%. The same
observation was also evident in the present study (2/12,
16.7%). As expected, a 4-break process was detected in cases
showing a classical t(9;22) stemline (as Case 12 in the present
study). Notably, it was also found in patients with a single
abnormal clone showing variant translocation (as Case 11 in
the present study). This suggests that a 4-break mechanism can
also operate at the initial stages of leukaemogenesis, either as
a one-step 4-break process or with a second translocation
between der(9)t(9;22) and a third partner chromosome
occurring shortly after t(9;22) in the same leukaemic stem
cell. These 2 scenarios are expected to be rare compared to a
simpler 3-break process. Therefore, the resulting 4-break D-
FISH pattern was less commonly observed in most series. We
recently reported a similar case of the unusual 4-break process
in a patient with acute promyelocytic leukaemia and a single
abnormal clone of 47,XY,+8,t(15;17;7)(q22;q12;q22) (12).
A major difficulty is seen when D-FISH is employed to
study how variant translocations arise in CML. It is not
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Table I. Disease status, full karyotype and D-FISH results.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Case No. Disease phase Karyotype D-FISH patterna Interpretation
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 Chronic 46,XY,t(5;9;22)(q31;q34;q11.2)[13] 89% 2G2O1F 3-break
11% 2G2O Residual normal cells
2 Chronic 46,XY,t(5;9;22)(q31;q34;q11.2)[7]/46,XY[1] 78% 2G2O1F 3-break
22% 2G2O Residual normal cells
3 Chronic 46,XX,t(9;22;10)(q34;q11.2;p14)[9] 100% 2G2O1F 3-break
4 Chronic 46,XX,t(9;22;10)(q34;q11.2;p14)[6] 100% 2G2O1F 3-break
5 Chronic 46,XY,t(9;22;14)(q34;q11.2;q32.1)[12] 100% 2G2O1F 3-break
6 Chronic 46,XX,t(5;9;22)(p15;q34;q11.2)[10] 100% 2G2O1F 3-break
7 Chronic 46,XY,t(9;22;17)(q34;q11.2;q25)[16] 100% 2G2O1F 3-break
8 Chronic 46,XY,t(7;9;22)(q35;q34;q11.2)[8] 100% 2G2O1F 3-break
9 Accelerated 46,XY,t(9;22;19)(q34;q11.2;q12.3)[5]/47,idem,+8[3] 100% 2G2O1F 3-break
10 Accelerated 46,XX,t(1;9;22)(q21;q34;q11.2)[8] 92% 2G2O1F 3-break
8% 2G2O Residual normal cells
11 Chronic 46,XX,t(4;9;22)(p11;q34;q11.2)[16] 19% 1G1O2F 4-break
81% 1G2O1F Loss of 3' BCR in subclone
12 Chronic 46,XX,t(9;22)(q34;q11.2)[2] 100% 1G1O2F 2-break in stemline
/46,XX,t(9;22;14)(q34;q11.2;q24)[9] 4-break in subclone
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aD-FISH pattern: G, green (BCR, 22q11.2); O, orange (ABL, 9q34); F, fusion (BCR-ABL; ABL-BCR).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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applicable to cases with der(9) deletion as one cannot deduce
whether a 3-break or 4-break process has occurred before the
deletion. This has been an important confounding factor as
der(9) deletion was observed in an average of 40% of cases in
most reported series (6). In the largest series reported to
date, Reid et al (5) detected a frequency of 3-break and 4-
break process in 52 and 11% of 54 patients with variant
translocation, respectively. However, a significant 37% of
the patients showed a der(9) deletion by D-FISH and thus a
translocation mechanism could not be assigned. As proposed
by Huntly et al (9), each recombination at der(9q34) should
have a finite probability leading to deletion around the region.
It is therefore reasonable to postulate that many, if not the
majority, of those cases with der(9) deletion had a 4-break
translocation. This would be in agreement with the finding that
in series with a low frequency of der(9) deletion (1) including
the present one, a much higher rate of 3-break events was seen
(83 to 94%). The suggestion that a 4-break mechanism can
also operate at the initial stages of leukaemogenesis and thus
predisposes to deletion, as discussed above, is also consistent
with the many evidences favouring a 9q deletion event
occurring at the time of formation of the Ph translocation (13).
The reason for the possible difference in rates of a 4-break
event among different series that might have explained the
observed variation in frequency of der(9) deletion is not
apparent. An ethnic genetic difference cannot be excluded. A
similar low rate of der(9) deletion (13.7%) was also reported in
a cohort of Chinese CML patients with variant translocations
(14). However, the rate of a 4-break event was not shown.
Three reported breakpoint hotspots in a third partner
chromosome (14q32, 17q25, 1q21) (2) were observed in our
cases. In addition, 2 cases each with breakpoint at 5q31 and
10p13 were found, which have not been found previously as
breakpoint hotspots. These breakpoint hotspots are located
preferentially in the GC-richest regions of the genome. GC-
rich regions have high densities of genes and repetitive Alu
sequences. They also coincide with open chromatin with high
transcription activities. These elements may increase the
chance of chromosome breakage and repair or the juxta-
positioning of Alu-rich sites, resulting in chromosomal
recombination and translocation (2).
In conclusion, complex variant translocation in CML
occurs more often as a 3-break single-step process with no
reciprocal ABL-BCR fusion. On the other hand, a 4-break
event is also regularly observed during the initial stages of
leukaemogenesis. Although by itself it may not have a
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Figure 1. Aypical D-FISH pattern in Case 12. (a) Complete karyotype showing 46,XX,t(9;22;14)(q34;q11.2;q24). (b) D-FISH analysis on a relocated G banded
metaphase with 1G1O2F. An ABL-BCR fusion signal is detected on der(9) (arrow), indicating a second break at 9q34 telomeric to the ABL breakpoint. No
signal is seen on der(14) (arrowhead).
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prognostic implication, a 4-break process likely predisposes to
der(9) deletion which is a strong predictor of survival. The
observed low frequency of der(9) deletion among Chinese
CML patients with variant translocations can be due to a low
rate of a 4-break event. Further studies confirming and
explaining this difference are warranted in order to have a
better understanding of the pathogenesis of CML.
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